UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

X	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________to

Commission File Number: 000-53854

EnzymeBioSystems

(Exact name of registrant as specified in its charter)

Nevada		27-0464302
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

8250 W. Charleston Blvd, Suite 120, Las Vegas, NV		89117
(Address of principal executive offices)		(Zip Code)

(702) 907-0615
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company, defined in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ]		Smaller Reporting Company [X]
(Do not check if a smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

There were 5,592,010 shares of Common Stock outstanding and issuable and 2,125,000 of its Series A Preferred Shares issued and outstanding as of February 20, 2018.

Table of Contents

EnzymeBioSystems

Index to Form 10-Q

For the Quarterly Period Ended December 31, 2017

PART I	Financial Information	3

ITEM 1.	Financial Statements	3
	Unaudited Interim Balance Sheets as of December 31, 2017 and June 30, 2017	3
	Unaudited Condensed Interim Statements of Operations for the three and six months ended December 31, 2017 and December 31, 2016	4
	Unaudited Condensed Interim Statements of Cash Flows for the six months ended December 31, 2017 and December 31, 2016	5
	Notes to the Condensed Interim Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	17

ITEM 4T.	Controls and Procedures	18

PART II	Other Information	21

ITEM 1.	Legal Proceedings	21

ITEM 1A.	Risk Factors	21

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21

ITEM 3.	Defaults Upon Senior Securities	21

ITEM 4.	Submission of Matters to a Vote of Security Holders	22

ITEM 5.	Other Information	22

ITEM 6.	Exhibits	22

	SIGNATURES	23

Part I. Financial Information

Item 1. Financial Statements

EnzymeBioSystems

Condensed Interim Balance Sheets

	December 31, 2017 (Unaudited)			June 30, 2017 (Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	427,155		$	41,249
Prepaid expense		6,000			3,000
Total current assets		433,155			44,249

TOTAL ASSETS	$	433,155		$	44,249

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	6,600		$	100
Accrued expenses		4,000			4,000
Total current liabilities		10,600			4,100

Total Liabilities		10,600			4,100

Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, 2,125,000 and 125,000 shares of Series A Preferred Stock issued and outstanding as of December 31, 2017 and June 30, 2017, respectively		2,125			125
Common stock, $0.001 par value, 195,000,000 shares authorized, 5,592,010 and 832,235 shares issued and outstanding as of December 31, 2017 and June 30, 2017, respectively		5,592			832
Additional paid-in capital		2,208,738			1,261,543
Accumulated deficit		(1,793,900	)		(1,222,351	)
Total stockholders’ equity		(422,555	)		40,149
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	433,155		$	44,249

The accompanying notes are an integral part of these financial statements.

EnzymeBioSystems

Condensed Interim Statements of Operations

(Unaudited)

	For the three months ended December 31, 2017			For the three months ended December 31, 2016			For the six months ended December 31, 2017			For the six months ended December 31, 2016
Revenue	$	-		$	-		$	-		$	-

Operating expenses:
Officers’ compensation (including stock- based compensation of $398,000, $0, $398,000 and $0 respectively)		422,500			18,000			439,000			36,000
Professional Fees		14,830			10,000			22,330			17,500
Investor Relations		99,200			-			99,200			-
Other		9,874			1,082			11,719			3,084
Total operating expenses		546,404			29,082			572,249			56,584

Loss from operations		(546,404	)		(29,082	)		(572,249	)		(56,584	)

Other income-(loss)					-
Restitution from former officer		300			-			700			-

Other income (loss)- net		300			-			700			-
Net (Loss)	$	(546,104	)	$	(29,082	)	$	(571,549	)	$	(56,584	)

Weighted average number of common shares outstanding - basic and diluted		3,636,465			832,235			2,300,049			832,235

Net loss per common share - basic and diluted	$	(0.15	)	$	(0.03	)	$	(0.25	)	$	(0.07	)

The accompanying notes are an integral part of these financial statements.

EnzymeBioSystems

Condensed Interim Statements of Cash Flows

(Unaudited)

	For the six months ended December 31, 2017			For the six months ended December 31, 2016

OPERATING ACTIVITIES
Net Loss	$	(571,549	)	$	(56,584	)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock-based compensation		398,000			-
Changes in operating assets and liabilities
Prepaid expenses		(3,000	)		(6,028	)
Accounts payable		6,500			200
Accrued expenses		-			-
Cash (used) by operating activities		(170,049	)		(62,412	)

FINANCING ACTIVITIES

Proceeds from sale of Units		551,955			-
Proceeds from sale of common stock to former chief executive officer		2,000			-
Proceeds from sale of Class A Preferred Stock to Berkeley Clinic, L.C.		2,000			-
Net cash provided by financing activities		555,955			-

NET INCREASE (DECREASE) IN CASH		385,906			(62,412	)
CASH - BEGINNING OF THE PERIOD		41,249			140,042
CASH - END OF THE PERIOD	$	427,155		$	77,630

SUPPLEMENTAL DISCLOSURES:
Interest paid		-			-
Income taxes paid		-			-

The accompanying notes are an integral part of these financial statements.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

December 31, 2017

(Unaudited)

NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December 31, 2017 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2017 audited financial statements. The results of operations for the period ended December 31, 2017 are not necessarily indicative of the operating results for the full year.

Basis of Presentation

In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.

Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K.

Reverse Stock Split

Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

December 31, 2017

(Unaudited)

NOTE 2 - GOING CONCERN

These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of December 31, 2017, the Company has not recognized any revenues and has accumulated losses of approximately $(1,793,900) since inception. The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s products, to provide financing for marketing and promotion, to secure property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds necessary to continue operations.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue recognition

The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to December 31, 2017, the Company has not recognized any revenues.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

December 31, 2017

(Unaudited)

Recent accounting pronouncements

On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018; early adoption is permitted.

The Company has early adopted ASU 2017-11. As a result, we have not recognized the fair value of the warrants containing down round features that were issued in the Private Offering from September 2017 to December 2017 (see Note 4) as liabilities.

Certain other accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.

NOTE 4 - STOCKHOLDERS’ EQUITY

The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock.

The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock, are not redeemable, and cannot be converted into Common Shares unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares.

From September 2017 to December 2017, the Company conducted a Private Offering with accredited investors to help fund the Company. The Company offered up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provided that Berkeley Clinic, L.C. (“Berkeley”) (holder of 75,000 shares of Common Stock and 125,000 shares of Series A Preferred Stock prior to Berkeley’s purchase of 2,000,000 shares of Series A Preferred Stock discussed in the fourth succeeding paragraph below) would maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in the Offering were exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September 6, 2017 to December 12, 2017, we sold a total of 2,759,775 Common Units to 16 investors at a price of $0.20 per Unit for gross proceeds of $551,955.

EnzymeBioSystems

Notes to the Condensed Interim Financial Statements

December 31, 2017

(Unaudited)

NOTE 4 - STOCKHOLDERS’ EQUITY (Continued)

The Class A, Class B and Class C warrants all expire August 31, 2022, and all provide for the reduction of their exercise prices if we directly or indirectly sell or grant any right with respect to our common stock or common stock equivalents at an effective price lower than the current exercise price of any of the Class A warrants.

Holders that exercise Class C warrants will receive Class D cashless warrants to receive additional shares of common stock at no cost in the event that the closing price of the common stock on the business day immediately prior to the date of exercise exceeds $0.40 per share.

On November 29, 2017, Gary Rojewski, the former CEO of the Company from June 2, 2014 to December 27, 2017, purchased 2,000,000 shares of unregistered restricted common stock in exchange for $2,000 cash. Mr. Rojewski was entitled to purchase these shares based on past services rendered the Company. The Company recognized officers’ compensation expense in the amount of $398,000, which represents the excess of the $400,000 estimated fair value of the 2,000,000 shares of common stock (using the $0.20 per share price used in the Private Offering) over the $2,000 purchase price.

On December 29, 2017, Berkeley Clinic, L.C. purchased 2,000,000 Shares of Series A Preferred Stock for $2,000, to maintain voting control of the Company, as was required pursuant to the Private Offering discussed in the fourth preceding paragraph above.

NOTE 5 - RELATED PARTY TRANSACTIONS

On September 17, 2017, the Company organized a Nevada corporation named LCNS as a subsidiary of the Company. On September 29, 2017, LCNS sold 2,000,000 restricted shares of LCNS common stock to T. J. Jesky (1,000,000 shares) and Mark DeStefano (1,000,000 shares) at a price of $.005 per share and $10,000 was deposited in LCNS’s attorney’s client trust account. Jesky and DeStefano are members of Berkeley Clinic, L.C. (See Note 4).

The sole officer and director of the Company is involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

NOTE 6 – PROVISION FOR INCOME TAXES

The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal income tax rate to income (loss) before provision for income taxes. The sources and tax effects of the differences are as follows:

	Six Months Ended December 31,
	2017			2016

Expected tax at 35%	$	(200,042	)	$	(19,804	)
Non-deductible stock based compensation		139,300			-
Increase in valuation allowance		60,742			19,804
Provision for (benefit from) income taxes	$	-		$	-

Deferred tax assets as of December 31, 2017 and June 30, 2017 are calculated as follows:

	December 31, 2017			June 30, 2017
Deferred tax assets:
Net operating loss carry forward		293,139		$	427,823
Less: valuation allowance		(293,139	)		(427,823	)
Net deferred tax assets	$	-		$	-

During the six months ended December 31, 2017, the Company recorded an increase in the deferred tax asset and the valuation allowance of $60,742 to recognize the tax effect of the $173,549 taxable loss (using a 35% effective ax rate) incurred in this period which management, as is the case with the entire $1,395,900 net operating loss carryforward at December 31, 2017, believes is not more likely than not will be realized. Also, the Company recorded a decrease in the deferred tax asset and the valuation allowance of $195,426 (from $488,565 to $293,139) to reflect the reduction of the United States corporate income tax rate from 35% to 21% effective January 1, 2018 resulting from The Tax Cuts and Jobs Act enacted on December 22, 2017. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income.

The net operating loss carryforward of approximately $1,395,900 at December 31, 2017 and approximately $1,222,351 at June 30, 2017 expires commencing in year 2029.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a significant change in ownership occur, net operating loss carryforwards may be limited as to use in the future.

The Company has no tax positions. All tax years remain subject to examination by taxing jurisdictions.

NOTE 7 – SUBSEQUENT EVENT

On February 16, 2018, the Securities and Exchange Commission announced the temporary suspension of trading in the Company’s securities from February 20, 2018 to March 5, 2018 because of questions regarding the accuracy of information in filings with the Commission, including a Form S-1 filed on January 11, 2018, a Form 8-K filed on January 4, 2018, and forms 10-K filed on September 20, 2016 and October 13, 2017 for the fiscal years ended June 30, 2016 and 2017, respectively, concerning, among other things, the company’s business operations and the identity of its officers.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “anticipate,” “believe,” “estimate,” “will,” “plan,” “seeks,” “intend,” and “expect” and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in this Quarterly Report on Form 10-Q All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Quarterly Report on Form 10-Q. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Critical Accounting Policies

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017.

Results of Operations

Overview of Current Operations

History and Organization

The Company was organized June 26, 2009 (Date of Inception) under the laws of the State of Nevada, as EnzymeBioSystems. On September 17, 2017, the Company incorporated LCNS in Nevada as a wholly owned subsidiary to conduct different business operations than the Company.

Our Business

EnzymeBioSystems researches specialty enzymes and enzyme related products. We utilize enzyme technologies to develop solutions for a broad range of applications within the specialty chemical industry. These markets are largely served by a small number of large, well-established businesses and research university centers. We plan to work collaboratively with those industrial companies to develop differentiated, high performance enzyme solutions for their target markets, and to leverage their well-developed distribution capabilities to better exploit commercial opportunities. Our enzyme technology will tie-in with development of new commercial biological active compounds. We hope we can develop specialty enzymes to eliminate the side effects and toxicity of the new commercially developed products.

Enzyme Industry

Enzymes can be categorized as “enzyme inhibitors” and “enzyme activators.” Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme’s activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Enzyme activators are molecules that bind to enzymes and increase their activity. These molecules are often involved in the allosteric [defined as having to do with a protein with a structure that is altered reversibly by a small molecule so that its original function is modified] regulation of enzymes in the control of metabolism. Both enzyme inhibitors and enzyme activators are currently used by many pharmaceutical and biotechnology companies in research and development of new drug compounds.

Enzymes also can be used as pharmaceutical products. Enzymes as pharmaceuticals have two important features that distinguish them from all other types of pharmaceutical products. First, enzymes often bind and act on their targets with great affinity and specificity. Second, enzymes are catalytic and convert multiple target molecules to the desired products. These two features make for what are considered specialized enzymes that can accomplish therapeutic biochemistry in the body that small molecules cannot. These characteristics have resulted in the development of many enzyme drugs for a wide range of disorders, e.g. insulin and interferon.

Business Strategy

We foresee our two areas of business opportunity, that include: 1) buying raw materials to produce specialty enzymes in our lab facility and offer these products for sale to research facilities and pharmaceutical companies; and 2) become a specialty contract manufacture for research universities and pharmaceutical companies that utilize enzymes in their research programs.

We plan to deploy our enzyme technologies across diverse markets that represent commercial opportunities in helping us build visibility for EnzymeBioSystems. We plan to use enzyme technologies to develop commercial solutions for a broad range of applications within the specialty chemical industry.

We currently have only limited resources and capability to develop, manufacture, market, sell, or distribute specialty enzyme products on a commercial scale. We will determine which specialty enzyme products to pursue independently based on various criteria, including: investment required, estimated time to market, regulatory hurdles, infrastructure requirements, and industry-specific expertise necessary for successful commercialization. At any time, we may modify our strategy and pursue collaborations for the development and commercialization of some specialty enzyme products that we had intended to pursue independently. In order for us to commercialize more specialty enzyme products directly, we plan to establish or obtain through outsourcing arrangements additional capability to develop, manufacture, market, sell, and distribute such products.

Marketing Strategy

Through our future independent and collaborative research and development programs, we plan to develop commercial enzyme products across multiple markets. In addition, we plan to develop a pipeline of enzyme product candidates that we expect to launch independently and/or in collaboration with strategic partners.

Competition

Our competitors have substantially greater financial, technical, and marketing resources than we do and may succeed in developing products that would render our products obsolete or noncompetitive. In addition, many of these competitors have significantly greater experience than we do in their respective fields. Our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner and are technologically superior to, and/or are less expensive than, other products on the market. Current competitors or other companies may develop technologies and products that are more effective than ours. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. The existing approaches of our competitors or new approaches or technology developed by our competitors may be more effective than those developed by us.

Any enzyme products that we develop will compete in multiple, highly competitive markets. For example, Codexis, Maxygen, Inc., Evotec, and Xencor have alternative evolution technologies. Integrated Genomics Inc., Myriad Genetics, Inc., and ArQule, Inc. perform screening, sequencing, and/or bioinformatics services. Novozymes A/S, Verenium Corporation, Genencor International Inc. and MPBiomedicals are involved in development, overexpression, fermentation, and purification of enzymes. Many of these competitors have significantly greater financial and human resources than we do. We believe that the principal competitive factors in our market are access to genetic material, technological experience and expertise, and proprietary position.

Our Current Business Strategy

Management is evaluating an enzyme compound which it believes has a specific therapeutic value in fighting tumors, specifically breast tumors. Management has undertaken research to study its synthetic Amooranin compound, which the Company has developed in-house. Some studies of Amooranin have already been completed in rats. Further, research is required to study Amooranin in a different animal species.

Amooranin, a triterpene acid with a novel structure isolated from the stem bark of Amoora rohituka, a tropical tree growing wild in India. Recent studies showed that multiple breast cancer cell lines respond to Amooranin in growth suppression assays. Mechanistic studies suggest that Amooranin suppresses growth factor signaling, induces cell cycle arrest, and promotes apoptosis. Because the anti-neoplastic activity of the plant-derived compound of Amooranin is relatively weak.

Amooranin-Me, our synthetic analogue was found to inhibit proliferation of several breast cancer cells with greater potency than the parent compound of Amooranin. Preliminary screening of Amooranin-Me in in-vitro experiments revealed some potency against breast cancer MCF-7 cells with concentrations down to the nanomolar range. All these studies indicate that Amooranin-Me is a promising drug with potential to be used for human breast cancer prevention.

The Company has moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Management wants to continue its research with Amooranin that will lead to the filing of an Investigational New Drug Application (“IND”) with the U. S. Food and Drug Administration. It is still too early to determine if this project has any potential value for the Company, and there are no assurances that the Company will ever be able to obtain an IND for this compound.

As of the date of this report, management of the Company has identified an independent chemical laboratory that can produce sufficient quantities of amooranin to proceed with the required animal studies. A small preclinical batch of methyl amooranin has been manufactured by the independent chemical laboratory. This preclinical batch is not large enough to sufficiently test in several animal studies needed to obtain an IND.

Recent Event

SEC Order of Trading Suspension

On February 16, 2018, the Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities of EnzymeBioSystems at 9:30 a.m. EST on February 20, 2018, and terminating at 11:59 p.m. EST, on March 5, 2018. The Commission temporarily suspended trading in the securities of EnzymeBioSystems because of questions regarding the accuracy of information in filings with the Commission, including a Form S-1 filed on January 11, 2018, a Form 8-K filed on January 4, 2018, and forms 10-K filed on September 20, 2016 and October 13, 2017 for the fiscal years ended June 30, 2016 and 2017, respectively, concerning, among other things, the company’s business operations and the identity of its officers. See added Risk Factor, in Part II, Item 1A below.

Patent, Trademark, License and Franchise Restrictions and Contractual Obligations and Concessions

We do not have any trademarks. In 2012, the two founders of the Company, along with a third party, as inventors, filed Patent Application # 14/369339 entitled “Amooranin Compounds and Analogs Thereof and Related Methods of Use.” The U.S. Patent Office informed us that they published the aforementioned pending Patent on December 4, 2014 (Publication No. 2014-0357711A1).

On November 28, 2017, we received from the U.S. Patent Office, Patent No. 9,828,326.

We plan to rely on trade secrets, technical know-how, and continuing invention to develop and maintain our competitive position. We will take security measures to protect our trade secrets, proprietary know-how and technologies, and confidential data and continue to explore further methods of protection. Our policy is to execute confidentiality agreements with our employees and consultants upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

Results of Operations for the three months and six months ended December 31, 2017

During the three month period ended December 31, 2017, the Company did not generate any revenues. In addition, the Company does not expect to generate any profit for the next twelve months.

For the three months ended December 31, 2017, we experienced a net loss of $(546,104) or $(0.15) per share as compared to a net loss of $(29,082) or $(0.03) per share for the same period last year. The net loss for the three months ended December 31, 2017 was attributed to $422,500 in officers’ compensation (including $398,000 stock-based compensation), $14,830 in professional fees, $99,200 in Investor Relations, and $9,874 in other operating expenses.

For the six months ended December 31, 2017, we experienced a net loss of $(571,549) or $(0.25) per share as compared to a net loss of $(56,584) or $(0.07) per share for the same period last year. The net loss for the six months ended December 31, 2017 was attributed to $439,000 in officers’ compensation (including $398,000 stock-based compensation), $22,330 in professional fees, $99,200 in Investor Relations, and $11,719 in other operating expenses.

Revenues

The Company has generated no revenues since its inception. As of December 31, 2017, the Company had an accumulated deficit of $(1,793,900). There can be no assurances that the Company can achieve or sustain profitability or that the Company’s operating losses will not increase in the future.

Going Concern

Our independent auditors included an explanatory paragraph in their report on the June 30, 2017 audited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors. Our ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and our ability to achieve and maintain profitable operations.

Therefore, management plans to raise equity capital to finance the operating and capital requirements of the Company. While the Company is devoting its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Plan of Operation

Management does not believe that the Company will be able to generate any significant profit during the coming year. Management believes developmental costs will most likely exceed its cash reserves for the coming year. Management is evaluating an enzyme compound, specifically a synthetic Amooranin which it believes has a specific therapeutic value in fighting tumors. Therefore, management will be required to seek outside funding, of at least $1,000,000.

Future funding could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to goodwill and other intangible assets, which could materially adversely affect the Company’s business, results of operations and financial condition. Any future acquisitions of other businesses, technologies, services or product(s) might require the Company to obtain additional equity or debt financing, which might not be available on terms favorable to the Company, or at all, and such financing, if available, might be dilutive.

Management hopes its research will identify an enzyme compound developed by the Company that will lead to the filing of an Investigational New Drug Application with the U. S. Food and Drug Administration. It is still too early to determine if this project has any potential value for the Company, and there are no assurances that the Company will ever be able to obtain an IND for this compound.

Summary of any product research and development that we will perform for the term of our plan of operation.

We plan to deploy our enzyme technologies across diverse markets that represent commercial opportunities in helping us build visibility for EnzymeBioSystems. We believe that this market approach might give us the ability to broadly apply our enzyme development and manufacturing capabilities while minimizing commercial risk in that research or pharmaceutical companies might change their needs during our development processes.

Expected purchase or sale of plant and significant equipment.

We have not purchased or sold any plant or significant equipment.

Significant changes in the number of employees.

As of December 31, 2017, we did not have any employees. We are dependent upon our one officer for our future business development. As our operations expand we anticipate the need to hire additional employees, consultants and professionals; however, the exact number is not quantifiable at this time.

Liquidity and Capital Resources

The Company is authorized to issue 195,000,000 shares of its $0.001 par value common stock and 5,000,000 shares of its $0.001 par value preferred stock. As of December 31, 2017, the Company has 5,592,010 shares of common stock issued and outstanding and 2,125,000 of its Series A Preferred Shares issued and outstanding. The numbers have been adjusted for a 1-for-20 reverse stock split that took place on October 19, 2017. As of December 31, 2017, the Company had current assets of $433,155 and current liabilities of $10,600.

The Company has limited financial resources available, which has had an adverse impact on the Company’s liquidity, activities and operations. In order for the Company to remain a Going Concern it will need to find additional capital or generate revenues. Additional working capital may be sought through additional debt or equity private placements, additional notes payable to banks or related parties (officers, directors or stockholders), or from other available funding sources at market rates of interest, or a combination of these. The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought. No assurances can be given that any necessary financing can be obtained on terms favorable to the Company, or at all.

EnzymeBioSystems’s Funding Requirements

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

Revenue Recognition: We will recognize revenue from product sales once all of the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services have been rendered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured.

New Accounting Standards

The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that any of these pronouncements will have a material impact on the Company’s financial position and results of operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4T. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Interim Accounting Officer, to allow timely decisions regarding required disclosures.

Management has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on such evaluation, management concluded that, our disclosure controls and procedures were not effective. Our disclosure controls and procedures were not effective because of the “material weaknesses” described below under “Management’s report on internal control over financial reporting,” which are in the process of being remediated as described below under “Management Plan to Remediate Material Weaknesses.”

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in rules promulgated under the Exchange Act, is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and affected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:

	●	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

	●	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our Board of Directors; and

	●	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting.

However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2017. In making its assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material weaknesses in our internal controls over financial reporting. As a result, our internal control over financial reporting was not effective as of December 31, 2017.

A “material weakness” is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. As a result of management’s review of the investigation issues and results, and other internal reviews and evaluations that were completed after the end of the year related to the preparation of management’s report on internal controls over financial reporting required for this annual report on Form 10-K, management concluded that we had material weaknesses in our control environment and financial reporting process which consisted of the following:

Deficiencies Related to the Design and Operation of Certain Company-Level Controls

	●	Non-compliance by the former chief financial officer with regards to unauthorized travel and entertainment expenses;

	●	Unauthorized personal charges by the former chief financial officer.

Deficiencies Related to the Design and Operation of Certain Accounting Procedures

	●	Inadequate accounting procedures responsible for processing payment requests by our former chief financial officer related to travel and entertainment expenditures

	●	Lack of clear procedures for ensuring appropriate expense controls.

In consultation with our board of directors and new interim accounting officer, we are implementing certain remediation measures, and we are in the process of creating and implementing additional remediation plans for the internal control deficiencies noted above. The remediation activities include:

Design and Operation of Certain Company-Level Controls

Management has conducted an internal investigation relating to the unauthorized travel and entertainment expenses, incurred by the former chief financial officer. We have identified various expenses by the Company’s former chief financial officer since February, 2015 that were inconsistent with Company policies or that lacked sufficient documentation. On September 21, 2015, the former chief financial officer was dismissed for cause, based on a breach of his fiduciary duties. The Board has subsequently appointed a new interim accounting officer and corporate secretary

We will implement a check-and-balance system to monitor all expenses.

Design and Operation of Certain Accounting Procedures

We expect to complete the following remediation during the remainder of 2018.

We will adopt a new policy and procedure that authorizes and reviews the accounting oversight by persons at the appropriate levels within the Company.

Changes in Internal Controls over Financial Reporting

On September 21, 2015, we replaced our former chief financial officer. We added a new interim accounting officer who has experience related to the application of generally accepted accounting principles and U.S. Securities and Exchange Commission rules and regulations as they pertain to financial reporting. We believe these personnel changes will strengthen our controls related to financial reporting. Other than these changes, there have been no other changes to our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1 — Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

In November 2015, the Company filed a complaint titled EnzymeBioSystems v. Edward C. Zimmerman III, Case No. A-15-727138-CV, filed in the District Court of the State of Nevada for Clark County. EnzymeBioSystems, the plaintiff in this matter, brought an action against Edward C. Zimmerman III, the defendant, for reimbursement of $38,567.95 in unauthorized expenditures. On July 24, 2017, Mr. Zimmerman was discharged from any debt owed to the Company via Chapter 7 Bankruptcy in the United States Bankruptcy Court, District of Nevada. As such, the Company cannot collect from Zimmerman in the state court action.

On January 26, 2017, Edward C. Zimmerman III entered into a Guilty Plea Agreement, in Nevada District Court, Case Number C-16-319713-1, using an Alford plea to attempted theft. He was ordered to pay restitution to the Company of $25,000 over the next three years. Through December 31, 2017, Mr. Zimmerman has sent the Company $700 in restitution. Mr. Zimmerman’s Chapter 7 Bankruptcy does not affect this Guilty Plea Agreement. He is still required to pay the $25,000 restitution to the Company over the next three years.

Item 1A - Risk Factors

See Risk Factors set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and the discussion in Part I, Item 2 above, under “Liquidity and Capital Resources.”

Suspension of Trading Risk Factor

On February 16, 2018, the Securities and Exchange Commission announced the temporary trading suspension of our common stock terminating on March 5, 2018. Following the suspension, we expect that our stock will be listed on the “grey sheets” under the symbol ENZB. The suspension of trading eliminated our market makers. It should be noted that a stock listed on the grey sheets is more difficult to sell as many market markers do not trade grey sheet companies. The listing on the grey sheets can hurt our investors by reducing the liquidity and market price of our common stock. In the absence of a trading market or an inactive trading market, investors may be unable to liquidate their investment or make any profit from the investment.

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds

In September, 2017, the Company began conducting a Private Offering, with accredited investors to help fund the Company. The Company offered up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Series A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Series B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Series C warrant exercisable at $0.60 per share of post reverse stock split common stock and upon the exercise of the Series C Warrants, the selling shareholder is entitled to one Series D cashless warrant of $0.40 per share of post reverse stock split common stock and the underlying common stock for the warrants.

The offering and sale of the Units in this Offering were exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September through December, 2017, the Company raised $551,955, representing 2,759,775 Common Units.

Item 3 — Defaults Upon Senior Securities

None.

Item 4 — Submission of Matters to a Vote of Security Holders

None.

Item 5 — Other Information

None.

Item 6 — Exhibits

Exhibit Number	Ref	Description of Document
31.1		Certification of Principal Executive Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EnzymeBioSystems
	Registrant

Date: February 20, 2018		/s/ John Dean Harper
	Name:	John Dean Harper
		Principal Executive Officer
		Principal Accounting Officer

EnzymeBioSystems 10-Q